Contra-indicated in patients with hypocalcemia.
Denosumab-bbdz (Jubbonti and Wyost) biosimilars. Approved 03/05/2024
- TRADE NAMES: Prolia (Amgen); Xgeva (Amgen)
- INDICATIONS: Osteoporosis (postmenopausal women), prevention of skeletal-related events in patients with bone metastases from solid tumors
- CLASS: Bone resorption inhibitor, Monoclonal antibody, RANK ligand (RANKL) inhibitor
- HALF-LIFE: 25–28 days
- FDA APPROVAL DATE: 06/01/2010
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Abatacept, Alcohol, Azacitidine, Betamethasone, Cabazitaxel, Denileukin, Docetaxel, Fingolimod, Gefitinib, Immuosuppressants, Leflunomide, Lenalidomide, Oxaliplatin, Pazopanib, Pralatrexate, Pralatrexate, Temsirolimus, Triamcinolone
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of denosumab in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 08/24/2024
